Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Employees
17,000
Headquarters
Website
Gilead Sciences Metrics
BasicAdvanced
$160bn
17.57
$7.35
0.33
$3.19
2.54%
Price and volume
Market cap
$160bn
Beta
0.33
52-week high
$157.29
52-week low
$104.46
Average daily volume
6.8m
Dividend rate
$3.19
Financial strength
Current ratio
1.967
Quick ratio
1.536
Long term debt to equity
99.744
Total debt to equity
99.744
Dividend payout ratio (TTM)
54.72%
Interest coverage (TTM)
11.94%
Profitability
EBITDA (TTM)
14,738
Gross margin (TTM)
79.37%
Net profit margin (TTM)
30.99%
Operating margin (TTM)
40.30%
Effective tax rate (TTM)
14.09%
Revenue per employee (TTM)
$1,750,000
Management effectiveness
Return on assets (TTM)
13.29%
Return on equity (TTM)
43.36%
Valuation
Price to earnings (TTM)
17.569
Price to revenue (TTM)
5.4
Price to book
6.85
Price to tangible book (TTM)
-126.83
Price to free cash flow (TTM)
15.696
Free cash flow yield (TTM)
6.37%
Free cash flow per share (TTM)
8.23
Dividend yield (TTM)
2.47%
Forward dividend yield
2.54%
Growth
Revenue change (TTM)
3.48%
Earnings per share change (TTM)
55.43%
3-year revenue growth (CAGR)
3.21%
10-year revenue growth (CAGR)
-0.99%
3-year earnings per share growth (CAGR)
18.49%
10-year earnings per share growth (CAGR)
-4.55%
3-year dividend per share growth (CAGR)
2.76%
10-year dividend per share growth (CAGR)
6.37%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
Business Wire·6 hours ago
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
Benzinga·3 days ago
Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Business Wire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs